Skip to main content

Table 1 Clinical information for altered and unaltered groups on cBioPortal

From: Increased expression of YTHDF1 and HNRNPA2B1 as potent biomarkers for melanoma: a systematic analysis

Clinical attribute

Statistical test

P-value

Q-value

Somatic status

Chi squared test

1.43 * 10−5

9.68 * 10−4

Biopsy time

Chi squared test

2.20 * 10−5

9.68 * 10−4

Cohort

Chi squared test

2.86 * 10−5

9.68 * 10−4

Tumor stage

Chi squared test

3.34 * 10−5

9.68 * 10−4

HLA_DPA2

Chi squared test

1.23 * 10−4

2.84 * 10−4

Tumor site

Chi squared test

3.12 * 10−4

4.71 * 10−4

Mutation count

Kruskal–Wallis test

3.76 * 10−4

4.71 * 10−4

Disease free status

Chi squared test

4.02 * 10−4

4.71 * 10−4

Cancer type detailed

Chi squared test

4.11 * 10−4

4.71 * 10−4

Oncotree code

Chi squared test

4.11 * 10−4

4.71 * 10−4

HLA_DPB2

Chi squared test

4.70 * 10−4

4.71 * 10−4

Durable clinical benefit

Chi squared test

4.87 * 10−4

4.71 * 10−4

RAF_RAS status

Chi squared test

6.57 * 10−4

5.49 * 10−4

HLA_DQA2

Chi squared test

6.68 * 10−4

5.49 * 10−4

HLA_DRB2

Chi squared test

7.09 * 10−4

5.49 * 10−4

Neo-antigen load

Kruskal–Wallis test

1.24 * 10−3

9.02 * 10−4

Serum lactate dehydrogenase

Kruskal–Wallis test

1.75 * 10−3

0.012

Dosage

Chi squared test

2.76 * 10−3

0.0178

Mutation load

Kruskal–Wallis test

3.62 * 10−3

0.021

Treatment response

Chi squared test

3.82 * 10−3

0.0211